keyword
MENU ▼
Read by QxMD icon Read
search

Macular edema anti-VEGF

keyword
https://www.readbyqxmd.com/read/28203470/unusual-presentation-of-type-1-idiopathic-macular-telangiectasia
#1
Zaïnab Bentaleb Machkour, Philippe Denis, Laurent Kodjikian
Purpose. To report unusual presentation of type 1A idiopathic macular telangiectasia (IMT). Methods. Two middle-aged women with bilateral IMT were examined. Results. Both patients presented with a gradual vision loss in both eyes. Fundus examination was unremarkable in one case and showed small macular telangiectasia in both eyes in the other case. Fluorescein angiography (FA) revealed early bilateral macular punctuated hyperfluorescence corresponding to the dilated capillaries in both cases. FA and fundus examination confirmed also the absence of vascular abnormalities in the middle or anterior fundus periphery in one case...
2017: Case Reports in Ophthalmological Medicine
https://www.readbyqxmd.com/read/28195619/efficacy-of-the-intravitreal-sustained-release-dexamethasone-implant-for-diabetic-macular-edema-refractory-to-anti-vascular-endothelial-growth-factor-therapy-meta-analysis-and-clinical-implications
#2
Zainab Khan, Robin K Kuriakose, Maryam Khan, Eric K Chin, David R P Almeida
BACKGROUND AND OBJECTIVE: To assess the effect on best-corrected visual acuity (BCVA) and efficacy of the intravitreal sustained-release 0.7 mg dexamethasone implant (Ozurdex; Allergan, Irvine, CA) in patients with recalcitrant diabetic macular edema (DME). PATIENTS AND METHODS: Meta-analysis utilizing the MOOSE framework and a random effects model. Studies included adults undergoing treatment with Ozurdex for DME. The methodologic quality of each study was assessed using the MINORS and the Cochrane Collaboration Risk of Bias for randomized studies...
February 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28178701/a-nonrandomized-open-label-multicenter-phase-4-pilot-study-on-the-effect-and-safety-of-iluvien%C3%A2-in-chronic-diabetic-macular-edema-patients-considered-insufficiently-responsive-to-available-therapies-respond
#3
João Figueira, José Henriques, Miguel Amaro, Vítor Rosas, Dalila Alves, José Cunha-Vaz
PURPOSE: The aim of this study was to assess the effectiveness and safety of ILUVIEN® in patients with chronic diabetic macular edema (DME) who were insufficiently responsive to prior therapies. METHODS: This is a prospective, nonrandomized, multicenter, open-label, phase 4 pilot study assessing the effectiveness and safety of ILUVIEN® involving 12 patients insufficiently responsive to available therapies. Assessments were performed at screening, baseline, week 1, and months 1, 3, 6, 9, and 12...
February 9, 2017: Ophthalmic Research
https://www.readbyqxmd.com/read/28160192/study-of-aqueous-cytokines-in-patients-with-different-patterns-of-diabetic-macular-edema-based-on-optical-coherence-tomography
#4
Sabyasachi Bandyopadhyay, Samir Kumar Bandyopadhyay, Mita Saha, Abhik Sinha
PURPOSE: To compare aqueous angiogenic and inflammatory cytokine concentrations in different patterns of diabetic macular edema (DME) based on optical coherence tomography (OCT). METHODS: This prospective study was conducted between July 1, 2015, and March 31, 2016, for 9 months. Aqueous samples were obtained from 52 consecutive DME patients and 16 controls. DME patients were divided according to OCT patterns into diffuse retinal thickening (DRT; n = 17), cystoid macular edema (CME; n = 20) and serous retinal detachment (SRD; n = 15) groups...
February 3, 2017: International Ophthalmology
https://www.readbyqxmd.com/read/28152535/the-blood-retinal-barrier-in-the-management-of-retinal-disease-euretina-award-lecture
#5
José Cunha-Vaz
Retinal diseases are the main causes of blindness in the Western world. Diabetic retinopathy and age-related macular degeneration continue to increase in prevalence and as main causes of vision loss. Intravitreal anti-VEGF and steroid injections have raised new expectations for their successful treatment. These agents act by stabilizing the blood-retinal barrier (BRB). Our group defined the BRB by identifying for the first time the tight junctions that unite retinal endothelial cells and are the basis for the inner BRB, an observation later confirmed in retinal pigment epithelial cells and in brain vessels...
February 3, 2017: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/28151747/the-early-treatment-diabetic-retinopathy-study-historical-review-and-relevance-to-today-s-management-of-diabetic-macular-edema
#6
Nidhi Relhan, Harry W Flynn
PURPOSE OF REVIEW: To provide an historical review of the Early Treatment Diabetic Retinopathy Study (ETDRS) in the management of diabetic macular edema (DME), and to discuss its relevance to the management of DME. RECENT FINDINGS: The ETDRS reported that argon laser treatment is beneficial in the management of 'clinically significant' DME. The study provided guidelines for the treatment with focal and/or grid laser based on fluorescein angiographic patterns. In today's world, with the advent of optical coherence tomography, 'clinically significant' DME is now classified into center-involved DME (CI DME) and noncenter-involved DME (non-CI DME)...
February 1, 2017: Current Opinion in Ophthalmology
https://www.readbyqxmd.com/read/28114569/optical-coherence-tomography-angiography-analysis-of-the-foveal-avascular-zone-and-macular-vessel-density-after-anti-vegf-therapy-in-eyes-with-diabetic-macular-edema-and-retinal-vein-occlusion
#7
Khalil Ghasemi Falavarjani, Nicholas A Iafe, Jean-Pierre Hubschman, Irena Tsui, Srinivas R Sadda, David Sarraf
Purpose: To evaluate the changes in foveal avascular zone (FAZ) area and the retinal capillary density after a single intravitreal anti-VEGF injection for macular edema secondary to diabetic retinopathy or retinal vein occlusion. Methods: In this prospective noncomparative case series, 18 eyes of 15 patients with diabetic macular edema (13 eyes) or macular edema secondary to central retinal vein occlusion (5 eyes) were included. Optical coherence tomography angiography (OCTA) images were obtained, and retinal capillary vessel density and FAZ area were measured in the foveal and parafoveal regions at the level of the superficial (SCP) and deep retinal capillary plexus (DCP) before and at the first visit after intravitreal injection...
January 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/28114356/co-evaluation-of-peripapillary-rnfl-thickness-and-retinal-thickness-in-patients-with-diabetic-macular-edema-rnfl-misinterpretation-and-its-adjustment
#8
Hyun Seung Yang, Jong Eun Woo, Min-Ho Kim, Dong Yoon Kim, Young Hee Yoon
We investigated the relationship between the peripapillary retinal nerve fiber layer and peripapillary retinal thickness in patients with diabetic macular edema. Fifty eyes (group I) with non-proliferative diabetic retinopathy and diabetic macular edema receiving intravitreal anti-VEGF injection, and 90 eyes (group II) without diabetic macular edema were included in this case-control study. The peripapillary retinal nerve fiber layer thickness, peripapillary retinal thickness, and a new retinal nerve fiber layer index using a modeled relationship between the two parameters were evaluated with spectral-domain optical coherence tomography, at baseline and at the 6-month follow-up...
2017: PloS One
https://www.readbyqxmd.com/read/28106889/the-incidence-and-risk-factors-for-the-development-of-vitreomacular-interface-abnormality-in-diabetic-macular-edema-treated-with-intravitreal-injection-of-anti-vegf
#9
C-K Chang, C-K Cheng, C-H Peng
PurposeTo report the incidence and associated factors for the development of vitreomacular interface abnormality (VMIA) in patients with diabetic macular edema (DME) who received intravitreal injection (IVI) of anti-VEGF (Bevacizumab and Ranibizumab) treatment.MethodsA retrospective observational study. Patients with DME followed at least 6 months were reviewed. Baseline best-corrected visual acuity (BCVA), central retinal thickness (CRT) and final BCVA, CRT in eyes with and without VMIA were compared. Multiple logistic regression was also used to investigate the risk factors of VMIA formation in patients with DME treated by anti-VEGF...
January 20, 2017: Eye
https://www.readbyqxmd.com/read/28106709/systemic-pharmacokinetics-and-pharmacodynamics-of-intravitreal-aflibercept-bevacizumab-and-ranibizumab
#10
Robert L Avery, Alessandro A Castellarin, Nathan C Steinle, Dilsher S Dhoot, Dante J Pieramici, Robert See, Stephen Couvillion, Maʼan A Nasir, Melvin D Rabena, Mauricio Maia, Sherri Van Everen, Kha Le, William D Hanley
PURPOSE: To evaluate the systemic pharmacokinetics (PKs) of aflibercept, bevacizumab, and ranibizumab in patients with neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), or retinal vein occlusion (RVO). METHODS: Prospective, open-label, nonrandomized clinical trial of patients with AMD, DME, or RVO who were antivascular endothelial growth factor (VEGF) naïve or had not received anti-VEGF for ≥4 months. Patients received 3 monthly intravitreal injections of aflibercept 2...
January 18, 2017: Retina
https://www.readbyqxmd.com/read/28031700/long-term-results-of-combination-therapy-using-anti-vegf-agents-and-dexamethasone-intravitreal-implant-for-retinal-vein-occlusion-an-investigational-case-series
#11
Michael A Singer, Michael E Jansen, Lyndon Tyler, Paul Woods, Faisal Ansari, Udit Jain, Joshua Singer, Darren Bell, Chelsey Krambeer
BACKGROUND: One limitation of anti-VEGF therapy is the need for monthly retreatment to maintain efficacy. The purpose of this study was to determine the duration of effect in eyes with macular edema (ME) secondary to branch or central retinal vein occlusion (BRVO or CRVO) treated with anti-VEGF therapy plus sustained-release dexamethasone (DEX implant; Ozurdex). MATERIALS AND METHODS: This open-label, interventional case series included 62 eyes with ME due to RVO, central foveal thickness (CFT) >300 μm, and best-corrected visual acuity (BCVA) of 20/40 or worse...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/27983657/fingolimod-associated-bilateral-cystoid-macular-edema-wait-and-see
#12
REVIEW
Refik Pul, Alma Osmanovic, Holger Schmalstieg, Amelie Pielen, Kaweh Pars, Philipp Schwenkenbecher, Kurt Wolfram Sühs, Özlem Yildiz, Benedikt Frank, Martin Stangel, Thomas Skripuletz
Fingolimod 0.5-mg once-daily is an approved therapy for patients with relapsing-remitting multiple sclerosis (MS). Several pivotal and real-world studies have demonstrated that fingolimod is associated with the development of macular edema (ME). Herein, we present a case of a diabetic MS patient who developed severe bilateral ME during fingolimod treatment. By means of this case study we provide a detailed review about fingolimod associated macular edema (FAME), its current incidence with or without diabetes mellitus, and previous therapy attempts and outcomes in MS patients...
December 14, 2016: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/27974593/lebecetin-a-c-type-lectin-inhibits-choroidal-and-retinal-neovascularization
#13
Fadoua Montassar, Marie Darche, Amandine Blaizot, Sébastien Augustin, Jean-Baptiste Conart, Aurélie Millet, Mohamed Elayeb, José-Alain Sahel, Annabelle Réaux-Le Goazigo, Florian Sennlaub, Naziha Marrakchi, Erij Messadi, Xavier Guillonneau
Angiogenesis is a cause of visual impairment and blindness in the wet form of age-related macular degeneration and in ischemic retinopathies. Current therapies include use of anti-VEGF agents to reduce choroidal neovascularization (CNV) and edema. These treatments are effective in most cases, but spontaneous or acquired resistance to anti-VEGF and possible adverse effects of long-term VEGF inhibition in the retina and choroid highlight a need for additional alternative therapies. Integrins αvβ3 and αvβ5, which regulate endothelial cell proliferation and stabilization, have been implicated in ocular angiogenesis...
December 14, 2016: FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology
https://www.readbyqxmd.com/read/27958226/correlation-of-vascular-endothelial-growth-factor-production-with-photochemical-reaction-induced-retinal-edema
#14
Liang Shan, Mi Zheng, Yuan Zhang, Yuan Qu, Tian Niu, Qing Gu, Kun Liu, Xin Xia
BACKGROUND: Retinal edema is the major complication of retinal vein occlusion and diabetic retinopathy; it can damage visual function by influencing macular region. This study was to establish a rat retinal edema model and explore the related VEGF expression and observe the responses to anti-VEGF drugs in this model. METHODS: A rat retinal edema model was established by inducing photochemical reaction using a 532 nm laser after the intravenous injection of Erythrosin B...
2016: Chinese Medical Journal
https://www.readbyqxmd.com/read/27918469/dietary-compound-chrysin-inhibits-retinal-neovascularization-with-abnormal-capillaries-in-db-db-mice
#15
Min-Kyung Kang, Sin-Hye Park, Yun-Ho Kim, Eun-Jung Lee, Lucia Dwi Antika, Dong Yeon Kim, Yean-Jung Choi, Young-Hee Kang
Diabetic retinopathy (DR) develops in a significant proportion of patients with chronic diabetes, characterized by retinal macular edema and abnormal retinal vessel outgrowth leading to vision loss. Chrysin, a naturally-occurring flavonoid found in herb and honeycomb, has anti-inflammatory, antioxidant, and anti-cancer properties. This study sought to determine the protective effects of chrysin on retinal neovascularization with abnormal vessels and blood-retinal barrier (BRB) breakdown in 33 mM glucose-exposed human retinal endothelial cells and in db/db mouse eyes...
December 3, 2016: Nutrients
https://www.readbyqxmd.com/read/27865689/retinal-oximetry-during-treatment-of-retinal-vein-occlusion-by-ranibizumab-in-patients-with-high-blood-pressure-and-dyslipidemia
#16
C Keilani, A Halalchi, D Wakpi Djeugue, A Regis, S Abada
INTRODUCTION: In the present study, we examined retinal vascular oxygen saturation in patients with retinal vein occlusion (RVO), high blood pressure (HBP) and dyslipidemia, before and during intravitreal vascular endothelial growth factor (VEGF) injection (ranibizumab). METHODS: We retrospectively reviewed the medical records of six patients with visual acuity (VA) reduced by macular edema (ME) secondary to RVO with HBP and dyslipidemia, who underwent intravitreal anti-VEGF injection between October 2014 and February 2015 in the department of ophthalmology of François-Quesnay Hospital at Mantes-la-Jolie (France)...
December 2016: Journal Français D'ophtalmologie
https://www.readbyqxmd.com/read/27863843/score2-report-2-study-design-and-baseline-characteristics
#17
Ingrid U Scott, Paul C VanVeldhuisen, Michael S Ip, Barbara A Blodi, Neal L Oden, Maria Figueroa, Pravin U Dugel
PURPOSE: To describe the design and baseline characteristics of participants in the Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2) and to compare with cohorts from other retinal vein occlusion trials. DESIGN: Phase III prospective, multicenter, randomized clinical trial designed to assess whether intravitreal bevacizumab is noninferior to intravitreal aflibercept for treatment of decreased vision attributable to macular edema associated with central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO)...
February 2017: Ophthalmology
https://www.readbyqxmd.com/read/27853011/long-term-effect-of-anti-vascular-endothelial-growth-factor-injections-on-intraocular-pressure
#18
Ashiyana Nariani, Blake Williams, Seenu M Hariprasad
OBJECTIVE: There is a substantial debate in the ophthalmology community about whether anti-vascular endothelial growth factor (VEGF) injections result in a long-term increase in intraocular pressure (IOP). DESIGN: We performed a retrospective study to investigate how the number and timing of intravitreal injections in patients with age-related macular degeneration (AMD) and diabetic macular edema (DME) affect IOP over time. METHODS: We collected long-term IOP data on patients receiving anti-VEGF injections at our institution...
September 2016: Indian Journal of Ophthalmology
https://www.readbyqxmd.com/read/27847634/initiation-of-intravitreal-aflibercept-injection-treatment-in-patients-with-diabetic-macular-edema-a-review-of-vivid-dme-and-vista-dme-data
#19
Focke Ziemssen, Patricio G Schlottman, Jennifer I Lim, Hansjürgen Agostini, Gabriele E Lang, Francesco Bandello
BACKGROUND: Diabetic macular edema (DME) shows a gradual and sustained functional and morphologic response to anti-vascular endothelial growth factor (VEGF) drugs, but the optimal schedule for initiation of anti-VEGF therapy is not known. This study evaluates the treatment response behavior of DME in the Phase 3 trials of intravitreal aflibercept, with 5 initial intravitreal aflibercept injections (IAI), 2 mg every 4 weeks (2q4), in the upload phase. METHODS: This post hoc pooled analysis of the VISTA-DME (NCT01363440) and VIVID-DME (NCT01331681) trials evaluated the change in best-corrected visual acuity (BCVA) and central retinal thickness (CRT) during the upload phase, using pooled data from both IAI treatment groups [2q4 and 2 mg every 8 weeks (2q8)]...
2016: International Journal of Retina and Vitreous
https://www.readbyqxmd.com/read/27826179/efficacy-of-single-bevacizumab-injection-as-adjuvant-therapy-to-laser-photocoagulation-in-macular-edema-secondary-to-branch-retinal-vein-occlusion
#20
Arief S Kartasasmita, Siska Takarai, Astriviani Switania, Sutarya Enus
BACKGROUND: Macular grid laser photocoagulation remains the standard treatment for macular edema secondary to branch retinal vein occlusion (BRVO). One possible strategy for treating macular edema is to inhibit VEGF activity by competitive binding of VEGF with an anti-VEGF antibody, suggesting the therapy option with bevacizumab. However, multiple injections of anti-VEGF may lead to complications and high cost. PURPOSE: The aim of this study was to evaluate the improvement in visual acuity and central macular thickness after combination therapy of laser photocoagulation with single intravitreal bevacizumab injection in macular edema secondary to BRVO...
2016: Clinical Ophthalmology
keyword
keyword
36615
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"